Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 3,236 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92. Following the completion of the sale, the insider now directly owns 162,898 shares of the company’s stock, valued at $4,678,430.56. This trade represents a 1.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, March 3rd, Soleil Boughton sold 4,151 shares of Hims & Hers Health stock. The stock was sold at an average price of $45.14, for a total transaction of $187,376.14.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total value of $89,863.72.
• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.69, for a total value of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $26.92 on Thursday. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company’s 50-day simple moving average is $37.94 and its 200 day simple moving average is $30.50. The firm has a market capitalization of $5.98 billion, a P/E ratio of 61.18 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. Leerink Partners upped their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Finally, BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $38.25.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. SlateStone Wealth LLC increased its position in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. raised its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after purchasing an additional 628 shares in the last quarter. Cim LLC boosted its position in shares of Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after buying an additional 694 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after buying an additional 833 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.